Related Experiment Videos
Insights
Neonatal erythrocyte transfusions are recommended for infants with anemia-induced heart failure and specific symptoms. Granulocyte transfusions may benefit critically ill neonates with sepsis, neutropenia, and low neutrophil stores.
Area of Science:
- Neonatal Medicine
- Hematology
- Pediatric Critical Care
Background:
- Neonatal transfusion practices, including erythrocyte 'booster' transfusions and granulocyte transfusions, are subjects of ongoing debate.
- Current guidelines for these transfusions in neonates require critical review and updated recommendations.
Purpose of the Study:
- To critically review controversial neonatal transfusion practices.
- To provide current recommendations for erythrocyte and granulocyte transfusions in neonates.
Main Methods:
- Literature review and critical analysis of existing studies on neonatal transfusion practices.
- Formulation of evidence-based recommendations for clinical application.
Main Results:
- Erythrocyte transfusions are indicated for neonatal congestive heart failure due to anemia.
- Erythrocyte transfusions may be beneficial for infants with anemia and symptoms like apnea or poor weight gain.
- Granulocyte transfusions are recommended for neonates with bacterial sepsis, neutropenia, and depleted neutrophil stores.
Conclusions:
- Erythrocyte transfusions should be administered to neonates with anemia-related congestive heart failure and specific clinical indicators.
- Granulocyte transfusions offer potential benefits for severely ill neonates with confirmed sepsis and specific hematological criteria.
- The use of granulocyte transfusions in neonates with fewer than three of the specified criteria should be considered experimental.
Abstract:
Two controversial issues of neonatal transfusion practices, erythrocyte 'booster' transfusions and granulocyte transfusions, are critically reviewed, and current recommendations for transfusion practices are made. Infants should receive erythrocyte transfusions to treat congestive heart failure caused primarily by anemia. It is customary to maintain the hematocrit at greater than 40% in neonates with severe respiratory disease, although the efficacy of this practice has not been firmly established. Erythrocyte transfusions seem to be indicated for infants with anemia plus recurrent apnea, poor weight gain or the syndrome of tachycardia, tachypnea, dyspnea and poor feeding for which no other cause can be found. Granulocyte transfusions are likely to benefit seriously ill neonates exhibiting all three of the following: strong evidence of bacterial sepsis, neutropenia (compared to age-related normal values) and a diminished marrow neutrophil storage pool. Granulocyte transfusions for septic infants expressing only one or two of these features should be considered to be experimental therapy.